中信建投：中国医药产业正站在全球化价值重估起点看好相关创新药及制药企业

智通财经01-22

智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。看好CXO行业龙头以及海外业务占比较高的公司，期待国内各CRO细分板块公司陆续迎来业绩拐点。本届JPM大会中国药企凭借ADC、IO双抗、GLP-1等领域的技术突破，通过License out及合作开发等方式走向全球。百济神州等龙头已实现组织出海，部分...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2605546621?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-22 16:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605546621","market":"sh","top_or_hot":-1,"title":"中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。看好CXO行业龙头以及海外业务占比较高的公司，期待国内各CRO细分板块公司陆续迎来业绩拐点。本届JPM大会中国药企凭借ADC、IO双抗、GLP-1等领域的技术突破，通过License out及合作开发等方式走向全球。百济神州等龙头已实现组织出海，部分...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1396127.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-22 16:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1396127.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。看好CXO行业龙头以及海外业务占比较高的公司，期待国内各CRO细分板块公司陆续迎来业绩拐点。本届JPM大会中国药企凭借ADC、IO双抗、GLP-1等领域的技术突破，通过License out及合作开发等方式走向全球。百济神州等龙头已实现组织出海，部分...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1396127.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0250","symbol_name":"批发","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1396127.html","article_id":"2605546621","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605546621","pubTimestamp":1769070647,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。整体看，中国医药产业正站在全球化价值重估的起点，2026年将成为验证转型成效的关键节点。中国药企呈现全球化提速的格局。中国CXO企业凭借ADC、双抗、GLP-1等领域的一站式服务平台能力，完成从“中间供应商”到“全球创新赋能者”的跃升。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","600056":"中国医药","601066":"中信建投","BK0250":"批发","BK0082":"国资改革","BK0010":"央企","BK0175":"白马股","BK0028":"国家队","01477":"欧康维视生物-B","BK0185":"二线龙头","BK1574":"生物医药B类股","BK0276":"资本市场","BK1191":"制药","BK0188":"融资融券","06978":"永泰生物-B","BK1161":"生物科技"},"translate_title":"CITIC Construction Investment: China's pharmaceutical industry is standing at the starting point of global value revaluation and optimistic about related innovative drugs and pharmaceutical companies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"600056":1.5,"601066":1.5,"06978":1.5,"01477":1.5},"content_text":"智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。看好CXO行业龙头以及海外业务占比较高的公司，期待国内各CRO细分板块公司陆续迎来业绩拐点。本届JPM大会中国药企凭借ADC、IO双抗、GLP-1等领域的技术突破，通过License out及合作开发等方式走向全球。百济神州等龙头已实现组织出海，部分Biotech实现细分领域突破。CXO板块，药明系企业凭借CRDMO模式与全球化产能布局，在手订单超持续增长，2026年海外基地密集投产，进入商业化收获期。整体看，中国医药产业正站在全球化价值重估的起点，2026年将成为验证转型成效的关键节点。国内药企方面，技术突破与全球化提速。中国药企呈现全球化提速的格局。核心趋势：1)ADC、多抗、小核酸等技术平台全面迭代，涌现多项BIC/FIC潜力资产;2)国际化进程加速，与MNC达成超百亿美金交易，创新药授权收入持续攀升;3)2026年国内药企进入催化剂密集兑现期，多家公司启动全球注册研究、关键数据读出及新产品申报，呈现个体密集突破与板块整体性提速的特征。国内CXO方面，平台赋能与全球化扩张。本届JPM大会凸显中国CXO产业从“成本优势”向“技术+规模”双轮驱动转变的历史性机遇。中国CXO企业凭借ADC、双抗、GLP-1等领域的一站式服务平台能力，完成从“中间供应商”到“全球创新赋能者”的跃升。2026年中外创新同步进入催化剂密集期，中国CXO在手订单持续增长，海外产能进入释放周期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605546621","isCrawlerRequest":true}

中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业

精彩评论

中信建投：中国医药产业正站在全球化价值重估起点看好相关创新药及制药企业